Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 8/20 | 0.44 |
| ▸ | RAB9A | P51151 | 8/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.42 |
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2629375 | 0.82 | SMYD3 (0.47) | SMYD3NPC1RAB9AMEN1KMT2A | |
| SCHEMBL12124245 | 0.82 | SMYD3 (0.47) | SMYD3NPC1RAB9AMEN1KMT2A | |
| SCHEMBL12181522 | 0.80 | SMYD3 (0.46) | SMYD3NPC1RAB9AMEN1KMT2A | |
| SCHEMBL107828 | 0.80 | SMYD3 (0.52) | SMYD3NPC1RAB9AMEN1KMT2A | |
| SCHEMBL20190429 | 0.78 | SMYD3 (0.48) | SMYD3NPC1RAB9AMEN1KMT2A | |
| SCHEMBL12124542 | 0.78 | SMYD3 (0.44) | SMYD3NPC1RAB9AMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL30015722 | 0.78 | SMYD3 (0.51) | SMYD3NPC1RAB9AMEN1KMT2A | |
| SCHEMBL12124262 | 0.77 | SMYD3 (0.51) | SMYD3NPC1RAB9AMEN1KMT2A | |
| SCHEMBL12124304 | 0.77 | SMYD3 (0.47) | SMYD3NPC1RAB9AMEN1KMT2A | |
| SCHEMBL12124441 | 0.77 | LMNA (0.47) | SMYD3NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210369716-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2021-12-02 | — | — | US | disclosed |
| US-11123348-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2021-09-21 | — | — | US | disclosed |
| US-20200179391-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2020-06-11 | — | — | US | disclosed |
| US-10596175-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2020-03-24 | — | — | US | disclosed |
| US-20190000852-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2019-01-03 | — | — | US | disclosed |
| US-9700559-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2017-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000852-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | TYR, TBCA, MAPT | SMYD3 3311/4885NPC1 111/4885RAB9A 1160/4885 |
| US-11123348-B2 | Compounds and compositions for the treatment of parasitic diseases | TYR, TBCA, MAPT | SMYD3 3311/4885NPC1 111/4885RAB9A 1160/4885 |
| US-10596175-B2 | Compounds and compositions for the treatment of parasitic diseases | TYR, TBCA, MAPT | SMYD3 3311/4885NPC1 111/4885RAB9A 1160/4885 |
| US-20210369716-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | TYR, TBCA, MAPT | SMYD3 3311/4885NPC1 111/4885RAB9A 1160/4885 |
| US-20200179391-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | TYR, TBCA, MAPT | SMYD3 3311/4885NPC1 111/4885RAB9A 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.